Hosted on MSN1mon
Olix, Eli Lilly to develop liver disease drug under $630 million deal
Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...
Business Wire1mon
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...